Clinical Trials Logo

Clinical Trial Summary

Study 4975-MN-202 is a double-blind, placebo-controlled, parallel group, single-injection study in which subjects will be randomized to receive three doses of CNTX-4975 or placebo injected into the intermetatarsal space around a Morton's neuroma. The injection of study medication will be administered by ultrasound-guided needle placement following ankle block anesthesia. The study staff will telephone subjects at Week 1 postinjection and subjects will return to the clinic postinjection at Weeks 2, 4, 8, and 12 for study assessments.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Neuroma
  • Pain
  • Painful Intermetatarsal Neuroma (Morton's Neuroma)

NCT number NCT02283957
Study type Interventional
Source Centrexion Therapeutics
Contact
Status Completed
Phase Phase 2
Start date October 2014
Completion date June 2016